Pregabalin: the battle continues

22 June 2017

Sheena Linehan discusses that with the cost of developing a new drug estimated at $2.5 billion, repurposing existing drug compounds for new indications is of increasing interest. However, patent and regulatory regimes arguably provide lesser incentives for second medical uses and an uncertain framework for patent enforcement.

Please see the full article here.


People tagged in this article:

Back to all news